-

FOXO Technologies™ Sets Second Quarter 2023 Business Update Call for Thursday, August 10, 2023 at 3:15 p.m. CT

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE_AM: FOXO), a leader in epigenetic biomarker discovery and commercialization, today announced that it will report financial results for the second quarter ended June 30, 2023 after market closes on Thursday, August 10, 2023.

Management will host a conference call to discuss second quarter 2023 results and recent business highlights at 3:15 p.m. Central time on Thursday, August 10, 2023. During the call, FOXO management will provide prepared remarks, followed by a question-and-answer period.

The call can be accessed via webcast on the investors section of the Company’s website at www.foxotechnologies.com/investors or by dialing (888) 770-7136 and referencing conference ID 4335886. Participants are encouraged to call in 10 to 15 minutes prior to the scheduled start time.

The webcast will be made available for replay on the Company’s website beginning approximately two hours after the event.

About FOXO Technologies Inc. (“FOXO”)

FOXO Technologies is a pioneering biotechnology company at the forefront of commercializing epigenetic biomarker technology. Their mission is to utilize the power of epigenetics and artificial intelligence to generate data-driven insights that promote optimal health and longevity outcomes for individuals and organizations alike. For more information about FOXO, visit www.foxotechnologies.com.

Contacts

Investor Relations
Matthew Hausch, Cody Slach
Gateway Investor Relations
(949) 574-3860
FOXO@gateway-grp.com

FOXO Technologies Inc.

NYSEAM:FOXO

Release Versions

Contacts

Investor Relations
Matthew Hausch, Cody Slach
Gateway Investor Relations
(949) 574-3860
FOXO@gateway-grp.com

More News From FOXO Technologies Inc.

FOXO Technologies Announces Agreement With Atrio Insurance

MINNEAPOLIS, Minn.--(BUSINESS WIRE)--FOXO Technologies Inc.™ (NYSEAM: FOXO), a technology platform company whose products and services seek to address long-standing, core problems within the life insurance industry through epigenetic longevity science, today announced that its insurance distribution subsidiary, FOXO LIFE™, has engaged Atrio Insurance/Singular Insurance Brokerage, an insurance brokerage general agency offering products and specialty programs throughout the United States, to sell...

FOXO Technologies Inc. Announces NYSE American Acceptance of Compliance Plan

MINNEAPOLIS--(BUSINESS WIRE)--On August 29, 2023, FOXO Technologies Inc. (the “Company”) (NYSEAM: FOXO) received a letter (the “Letter”) from NYSE American LLC (“NYSE American”) stating that NYSE American reviewed and accepted the plan of compliance (the “Plan”) submitted by the Company in response to NYSE American’s June 12, 2023 notice (the “Notice”) informing the Company that it was not in compliance with the continued listing standards set forth in Section 1003(a)(i) of the NYSE American Co...

FOXO Technologies Inc. Announces Receipt of Second Notice of Non-Compliance from NYSE American

MINNEAPOLIS--(BUSINESS WIRE)--On August 16, 2023, FOXO Technologies Inc. (NYSEAM: FOXO) (the “Company”) received a second written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that it is not in compliance with the continued listing standard set forth in Section 1003(f)(v) of the NYSE American Company Guide (the “Company Guide”) because the Company’s Class A common stock was selling for a low price per share for a substantial period of time, which NYSE American d...
Back to Newsroom